Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boston Pharmaceuticals
Biotech
GSK pays $1.2B upfront for Boston's lead liver disease drug
GSK is brushing off dropping a cancer asset on Tuesday by snagging a late-stage liver disease drug for a hefty $1.2 billion upfront.
Ben Adams
May 14, 2025 2:53am
Boston's monthly MASH prospect hits goal in phase 2
Nov 15, 2024 11:00am
Sanofi, Lilly, Amarin & more—Chutes & Ladders
Jun 7, 2024 8:30am
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
Jun 21, 2023 7:15am
Pieris puts phase 2 cancer drug out on chopping block
Aug 4, 2022 4:15pm
Moderna CFO Gomez departs after just one day—Chutes & Ladders
May 13, 2022 9:30am
